businesspress24.com - Healthcare & Medical: Pressemitteilungen - Kategorie - Seite 4
 

Healthcare & Medical

Category / Healthcare & Medical


Where is the next Chinese drug that will make MNCs compete to grab orders?

HONG KONG: HONG KONG, Jan 9, 2025 - (ACN Newswire) – The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders franticall ...

Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy

SHANGHAI: SHANGHAI, China - January 2, 2025 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical d ...

Worlds first high-standard negative-pressure isolation ward built with MiC technology completes historical mission

HONG KONG: Laid solid foundation for modular design in isolation facility construction technology ...

Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year

TOKYO: TOKYO, Dec 24, 2024 - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced that it has be ...

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Shanghai: - by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis ...

Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership

HONG KONG: HONG KONG, Dec 11, 2024 - (ACN Newswire) – As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical compa ...

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

SHANGHAI: - Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. - ...

Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong

SHANGHAI: SHANGHAI, Dec 2, 2024 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, ...

NEFECON(R) Included in National Reimbursement Drug List (NRDL)

HONG KONG: - Significantly Boosting Market Penetration and Driving Valuation Reassessment ...

Everest Medicines Announces NEFECON(R)s Full Approval in South Korea

HONG KONG: - Marking Another Milestone in Commercialization ...

HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLDs The Liver Meeting 2024

HONG KONG: - Demonstrating Benefits of Berberine Ursodeoxycholate (HTD1801) ...


Page 4 von 301:  « ..  3 4 5  6  7  8  9  10  11  12  .. » 301





 

Who is online

All members: 10 590
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 212


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.